Biofrontera

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biofrontera reports Q1 recovery post cyberattack, eyes product expansion

Biofrontera Inc. navigated challenges in Q1 2024, with a cyberattack impacting revenues, but recovery and growth were evident by April 30, 2024.
The company's strategic strengths lie in cost reduction through renegotiations, successful fundraising efforts, and advancements in clinical trials and product development.
Opportunities abound for Biofrontera with upcoming product launches, FDA approvals, and a focus on operational efficiency and financial management to drive future profitability.
Addressing financial challenges and leveraging opportunities will be key for Biofrontera to sustain growth, enhance market position, and deliver value to stakeholders in the coming quarters.

Biofrontera reports robust Q2 sales growth and cost efficiencies

Biofrontera delivered strong sales growth and cost management in Q2 2024, improving financial performance.
While challenges like net losses persist, opportunities exist to leverage momentum for sustained growth.
The company's focus on operational efficiency and revenue expansion sets the stage for future success and value creation.

Biofrontera reports steady Q3 growth amidst operational challenges and opportunities

Biofrontera Inc. showed resilience with revenue growth despite challenges like delayed deliveries.
Strategic strengths include FDA approvals, positive trial results, and focus on operational efficiency.
Challenges in high operating expenses and negative EBITDA highlight areas for improvement.
Opportunities lie in market expansion, clinical trial progress, and strategic financial management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WOBURN, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the launch of a randomized, double-blind, vehicle-controlled, multicenter Phase 3 clinical study to evaluate the safety and efficacy of Ameluz® and BF-RhodoLED® XL in the field-directed treatment of actinic keratosis (AK) on the extremities, neck and trunk. The study is being managed by Biofrontera Bioscience GmbH.

Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk

Biofrontera, Inc. (NASDAQ:BFRI ) Q3 2022 Earnings Conference Call November 14, 2022 11:00 AM ET Company Participants Tirth Patel - LHA Investor Relations Fred Leffler - CFO Erica Monaco - CEO, COO, Treasurer & Secretary Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Biofrontera Inc. Third Quarter Earnings Conference Call. [Operator Instructions].

Biofrontera, Inc. (BFRI) Q3 2022 Earnings Call Transcript

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of 28.13% and 0.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Biofrontera Inc. (BFRI) Reports Q3 Loss, Tops Revenue Estimates

Conference call begins at 11:00 a.m. Eastern time today

Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update

WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2022 before the opening of the U.S. financial markets on Monday, November 14, 2022. The Company will hold a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.

Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022

WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the exercise in full of options to purchase 2,623,365 ordinary shares of Biofrontera AG. These options were acquired in a private exchange agreement as announced on October 31, 2022, and were exercised at no additional cost. Furthermore, Biofrontera Inc. announced the purchase of additional 1,601,318 shares of Biofrontera AG.

Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG

WOBURN, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it has entered into private exchange agreements with certain holders of options to acquire ordinary shares of Biofrontera AG (the “AG Options”) in exchange for 3,148,042 newly issued shares of Biofrontera Inc. common stock.

Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG

WOBURN, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Fred Leffler as Chief Financial Officer, effective immediately. Mr. Leffler is an experienced financial executive with 15 years of leadership, financial management, consultancy and operations experience across a range of private and public organizations, including growth-stage, private equity and Fortune 100 companies.

Biofrontera Inc. Names Fred Leffler as Chief Financial Officer

WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that Erica Monaco, Chief Executive Officer, will be presenting and meeting with registered investors at the LD Micro Main Event XV that will be held October 25-27, 2022 at the Luxe Sunset Boulevard Hotel in Southern California.

Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference

Four Posters Highlight ing Results from Investigator-Initiated and Company-Sponsored Research with Ameluz to be Presented

Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference

WOBURN, Mass., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”) , a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that its Board of Directors has adopted a limited duration shareholder rights plan (the “Rights Plan”), and declared a dividend distribution of one preferred stock purchase right on each outstanding share of common stock, in order to protect the interest of all of the Company's shareholders. The rights will be issued to shareholders of record on October 24, 2022 and will expire on October 13, 2023.

Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan

WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Friday, October 14, at 10:00 AM EDT, and Tuesday October 18, at 1:00PM CDT. Biofrontera Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.

BIOFRONTERA INC. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022

WOBURN, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary unaudited product revenues for the three and nine months ended September 30, 2022.

Biofrontera Inc. Announces Preliminary Product Revenues for the Third Quarter of 2022

WOBURN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that Erica Monaco, Chief Executive Officer, will present at the Roth Inaugural Healthcare Opportunities Conference being held at the Yale Club in New York City on October 6, 2022. Management will also be participating in one-on-one investor meetings at the conference.

Biofrontera Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference

WOBURN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that PM360, a publication for marketing decision makers in the pharmaceutical, biotech, diagnostics and medical device industries, has awarded the previously nominated Ameluz® marketing campaign, created by Biofrontera Inc. along with Elevate Healthcare, “Relaunch/Revitalization of the Year” and “Professional Website/Online Initiative of the Year” awards. These awards were announced at the 14th Annual Trailblazer Awards held September 22, 2022 in New York, where they also recognized the previously announced Trailblazer Brand Champion in Dermatology, Leslie Hopkins, Associate Director of Marketing at Biofrontera Inc. The winners will be featured in the October issue of PM360 and on www.pm360online.com.

Biofrontera Inc.'s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards

WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Gerard DiGirolamo as National Sales Director. In this newly created position, Mr. DiGirolamo will report to Mark Baldyga, Biofrontera's Head of Sales & Marketing, and will help execute the Company's U.S. sales division and objectives including the strategic design, expansion and leadership of its sales team. He will oversee recruiting and staffing to support Ameluz®, BF-RhodoLED® and Xepi® commercial efforts, as well as spearhead planning for the launch of BF-RhodoLED XL®.

Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director

Company also granted special designation that enables expedited review of a recent U.S. patent application relating to novel PDT illumination protocols

Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion Composition-of-Matter U.S. Patent

Alaunos Therapeutics

Yatsen Holding

Penny stocks to watch with relative strength in the stock market today. The post Best Penny Stocks To Watch After Powell's Jackson Hole Speech appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Watch After Powell's Jackson Hole Speech

WOBURN, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that PM360, a publication for marketing decision makers in the pharmaceutical, biotech, diagnostics and medical device industries, has named Leslie Hopkins, Associate Director of Marketing, as a Trailblazer Brand Champion in the Dermatology category. The Ameluz® marketing campaign, created by Biofrontera Inc. along with Elevate Healthcare, also received nominations for PM360's “Relaunch/Revitalization of the Year” and “Professional Website/Online Initiative of the Year” awards.

Biofrontera Inc.'s Leslie Hopkins Named PM360 Trailblazer 2022 Brand Champion for Dermatology

Biofrontera Inc. (NASDAQ:BFRI ) Q2 2022 Earnings Conference Call August 12, 2022 11:00 AM ET Company Participants Tirth Patel - LHA Investor Relations Hermann Lubbert - Executive Chairman Erica Monaco - Chief Executive Officer Conference Call Participants Jonathan Aschoff - ROTH Bruce Jackson - The Benchmark Company Operator Welcome to the Biofrontera Inc. Second Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in listen-only mode.

Biofrontera Inc.'s (BFRI) CEO Erica Monaco on Q2 2022 Results - Earnings Call Transcript

Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update

Patent Improves Differentiated Profile of Ameluz-PDT by Expected Reduc ed Pain Intensity while Maintaining Efficacy

Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH

WOBURN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it has entered into agreements with certain of its holders of its existing warrants for 2,857,143 shares of its common stock, in the aggregate. Pursuant to the agreement such holders will promptly exercise their warrants in full, in accordance with their terms, including any beneficial ownership limitations. In return, the strike price was reduced by the Company from $5.25 to $1.62 per share and the Company agreed to issue in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), new warrants to purchase up to 4,285,715 shares of its common stock. The new warrants have a strike price of $1.66 per share of common stock and will be exercisable six months from the date of issuance. The aggregate gross proceeds from the exercise of the existing warrants and the issuance of the new warrants are expected to total approximately $4.69 million, before deducting the financial advisory fees.

Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement

Great Panther Silver

Verb Technology Company Inc

Are penny stocks on your list right now? The post Are Penny Stocks Worth It In 2022?

Are Penny Stocks Worth It In 2022? What To Know Now

Named A mong the 10 Fastest - Growing Life Sciences Companies to Watch in 2022 by CIOCoverage Magazine

News for Biofrontera Stock (BFRI)